ABSTRACT
Introduction
Currently, the agents with more effects on progression-free survival and overall survival are the combinations of different drugs such as Thalidomide, Bortezomib, Alkylating agents (Cyclophosphamide), Anthracyclines (Doxorubicin) and more recently second generation immunomodulators (Lenalidomide) and the new Proteosome Inhibitors [1] [2] [3] [4] [5] .
This combination of regimens in the induction of remission improves the overall response and the depth of the response by increasing the percentage of patients who achieved complete response (CR) [6] [7] [8] . However, the initial therapy in MM depends on risk stratification, patient conditions and availability of resources. Therefore, numerous regimens have been tested for the treatment of MM, separating those patients that are candidates from those patients who are not candidates for AHCT because progression-free survival and overall survival are better [9] [10] [11] [12] .
For now, it is well known the superiority of regimens containing Bortezomib-Dexamethasone. The data supporting their uses come from single-arm trials or from randomized studies that compare these regimens with others that are not considered as first-line [13] [14] [15] .
Some comparisons have been made with regimens containing Bortezomib plus Dexamethasone with Thalidomide (VTD) or with Cyclophosphamide (VCD) where it has been reported after 4 cycles of treatment that 66% of patients with VTD had at least VGPR vs. 56.2% for VCD arm (P = 0.05), and with better impact on Overall Response with VTD arm of 92.3% vs 83.4% in VCD arm (P = 0.01) [16] [17] [18] [19] [20] .
For adults older than 65 years, regimens have been compared in retrospective studies. For example, in a study in which the results of patients in this age with Melphalan-Prednisone -Thalidomide (MPT) regimens were compared vs. Bortezomib-DexamethasoneDoxorubicin with a PFS of 80 months in the MPT group and in the VAD group median was not reached (P = 0.03) [21] [22] [23] [24] [25] .
There are no studies so far that compare the different Bortezomibbased treatment regimens in Mexico and even in Latin America.
Endpoints
Primary Endpoints were to compare Overall Survival (OS), Progression-Free Survival (PFS) and Response Rates. As Secondary Endpoints, to determine the factors that affect PFS and to know the incidence of adverse events. The primary objective was to know and compare the response to treatment, overall survival, progression-free survival, and as secondary objectives to determine if there are prognostic factors that have an impact on progression-free survival by treatment group and to know the toxicity by treatment regimen.
Patients and Methods
The information was obtained from clinical files, electronic records and follow-up sheets. This study was approved by the Centro Médico Nacional 20 de Noviembre Hospital Research Committee, number 338.2017, which is subject to Declaration of Helsinki guidelines and Guide on Research Involving Human Subjects, guaranteeing respect for the following principles: Beneficence, Autonomy, Non-maleficence and Justice. And according to General Law of Health, article 100, chapter V. This investigation did not exist, Researchers or Institutions were not interested.
Statistical Analysis
Nominal variables were shown in percent, numerical variables were shown in mean, median, minimum, maximum and standard deviation. t-student test was used to compare numerical variables and they were corroborated with Kruskal-Wallis test and ANOVA table. Chi-square test was used to compare nominal variables and they were corroborated by Pearson's chi-squared test.
Descriptive analysis was performed with measures of central tendency and dispersion, absolute measures and percentages according to the type of variable. Measures of association and statistical significance (risk rates and p-value), were used for a univariate analysis with obtained data and its association with progression was evaluated.
Search for prognostic data was performed with ANOVA, Chisquare and t-student tests. Linear regression was used for the univariate and multivariate analysis. OS, PFS were calculated with the Kaplan-Meier nonparametric method as the median survival in months, an overall survival curve was made.
Statistical significance was considered with a p<0.05 value. To carry out the statistical tests and to obtain the survival curves, the statistical program SPSS 23.0 (SPSS Inc. Chicago, Illinois, USA) was used.
Results
From January 2010 to 2015, 201 patients were included, 88 women (44%), 113 men (56%) older than 18 years, of any sex, regardless of previous comorbidities. Demographic characteristics by treatment group were balanced. The proportion according to its functional state was, ECOG <2 =150 patients (75%) y ECOG >2 = 50 patients (25%). Bence-Jones was positive in 82 (41%), negative in 119 (59% The distribution by Durie-Salmon, immunoglobulin type, ISS, was practically similar between groups.
The overall response rate in the following was found for group BORCIC with CR/VGPR in 87%; in group BORDOX: with CR/VGPR in 69%; and in group BORTAL with CR/VGPR in 92% ,being similar between group BORTAL and BORCIC but significantly different from group BORDOX (p= 0.006). Progression was greater in group 2 (BORDOX), n = 36), compared with group 1 (BORCIC, n = 27) and group 3 (BORTAL, n = 10), while this last group has shown to be the best regimen in this item (p 0.04) In Progression-Free Survival analysis by treatment group, superiority was also found for group BORTAL, reaching a median of 36 months, followed by group BORCIC with a median of 28 months and finally group BORDOX with a median of 20 months (p 0.006). In the univariate analysis it was found that high Durie-Salmon Stage and elevated LDH (Lactate Dehydrogenasea) represent adverse prognostic factors for progression-free survival, (HR 1.9, 95% CI, 1.1-3.1, p 0.005 and HR 1, 95% CI, 0.9-1.1, p 0.02, respectively). In the multivariate analysis, the Durie-Salmon Stage maintained its impact as a prognostic factor, (HR 1.7, 95% CI, 0. As for toxicity, an overall incidence of neuropathy of 66% (132) was found. In the analysis by group, no significance was found BORCIC, n = 46, BORDOX n = 39, BORTAL n = 47, p 0.77). Neuropathy Grade 3-4 was higher in BORTAL arm (n=34) in comparison with BORDOX (n= 17) and BORCIC (n=19). (p=0.02). An overall incidence of Herpes Zoster of 12% (n= 24), with no differences found by treatment group (p 0.42).
Discussion
In this multicenter prospective cohort study, 3 different triplet bortezomib-based chemotherapies were analyzed. Patients who had completed at least 4 treatment cycles and who have the necessary data to assess the disease were analyzed.
Treatment groups were named by the name they receive in the Procedures Manual of the Hematology Service of that Medical Center. Baseline characteristics of each group were very similar. We emphasize that for Cyclophosphamide regimen, it is administered intravenously, unlike other regimens (CyBORD for example) because ISSSTE (Social Security Institute for Federal Government Employees) has no oral cyclophosphamide.
As expected, the immunoglobulin type with the highest prevalence was type G, followed by type A and non-secretory type in which the light chains subgroup was included.
An incidence of renal failure similar to that reported in other groups of 21% was found. In these reports, a correlation of subjects with renal failure at diagnosis with early mortality of 19.5 versus 40.4 months was found [26, 27] .
However, these reports are before the advent of Bortezomib. After the advent of Bortezomib, overall survival in patients with renal failure was compared in retrospective studies, finding lower overall survival in those with glomerular filtration rates lower than 60 ml/ min/m2, but no statistical significance was found [28] . We did not find an impact on progression-free survival when patients started the study with renal failure. This is attributable to the benefit of the drug in this population.
Despite the fact that most patients had in advanced ISS stages and a high tumor burden by Durie-Salmon Stage, this did not imply an impact on progression rate in the multivariate analysis. It is essential to explain that the above mentioned is attributable to the fact that the time to start the treatment is late, allowing more advanced stages to be established, but without having an impact on the incidence of renal failure. We did not find that renal failure was a prognostic factor in PFS and OS, perhaps because most patients had resolution during treatment.
As for Response to Treatment, comparisons with study drugs additional to Bortezomib, there are reports with Bortezomib, Dexamethasone, Thalidomide (VTD) vs. Bortezomib, Dexamethasone, Cyclophosphamide (VCD) in patients with recent Myeloma diagnosis and as an induction treatment prior to transplantation. This group found that the VTD combination increased more than 3 times the complete response rate compared to VCD (19 vs. 6%, p 0.001). Similarly, overall response rates were higher in the VTD arm than in the VCD arm [14, 30] .
We did not have primary refractoriness in studied patients, finding some type of response in all of them. The regimens with the best response (CR+VGPR were included here) was the regimen with Thalidomide (BORTAL), followed by the combination with Cyclophosphamide (BORCIC) and finally with Doxorubicin, which contrasts with some other groups that compared the Cyclophosphamide group vs. Doxorubicin, without finding differences in response rates [16] . However, among the group of Thalidomide (BORTAL) and Cyclophosphamide (BORCIC) a minimal difference was found in favor of the BORTAL group with respect to overall response rates.
In our analysed population, we found that factors with prognostic impact, with significant risk rates for progression-free survival and overall survival, were the type of achieved response with a non-achieved mean for those subjects with Complete Response. Although, generally, the treatment arm was not relevant while a complete response was reached, the benefit was derived from the Thalidomide and Cyclophosphamide arms. In summary, because most of the patients who achieved this type of response were in the group with Thalidomide followed by the group with Cyclophosphamide, these had a greater impact on the ProgressionFree Survival and Overall Survival.
Although most of these patients had advanced ISS stages and a high tumor burden, a large proportion of them had a functional status by ECOG equal to or less than 2, so we did not find a direct association between these factors.
Some studies, such as phase III HOVON-65/GMMG-HD4, compare the Vincristine, Doxorubicin and Dexamethasone (VAD) regimen vs. Bortezomib, Doxorubicin and Dexamethasone (PAD), finding greater progression-free survival with PAD, from 13 to 30 months in high-risk patients [11] . However, there are few direct comparisons in survival between different Bortezomibbased regimens, some are with drugs such as Lenalidomide vs. Cyclophosphamide [29] .
It is noteworthy that the overall rate of neuropathy was higher than in other groups, in which the reported incidence of neuropathy was 7% to 22% for the VTD combination compared to 1% to 13% for VCD [14, 30] .
The highest rates of neuropathy were in the BORTAL arm. In the analysis by Level of Neuropathy, the severity (grades 3 and 4) was higher in the combination with Thalidomide that justified the adjustment in the doses without affecting the responses in this treatment group. We concluded that this higher toxicity rate was because, Bortezomib was administered intravenously in our first patients.
The incidence of Herpes Zoster even with Acyclovir prophylaxis was similar to that reported by other groups. There was no difference by treatment group, corroborating in our universe of patients that the risk factor for the development of this infection is due to Bortezomib, without affecting the rest of the drugs.
As for mortality rates, these were greater with the regimen that included Doxorubicin, with significance with respect to the other two regimens in which the rates were similar. This led to the discontinuation of BORDOX regimen from our treatment protocols. On the other hand, in addition to the above, the highest rates of progression also were within the BORDOX regimen, suggesting that mortality in this treatment regimen was due to complications of the disease or comorbidities such as Diabetes Mellitus, Ischemic Heart Disease and other unspecified conditions, but not due to adverse drug events.
In Mexico due to financial issues in Public Health there is less availability of Bortezomib for the treatment of Multiple Myeloma. The records that evaluate the drug in our population are null, so the interest arose to report our results for these three drug-based regimens and to extend the scope to the authorities of our country.
Conclusion
In our experience, the best first-line treatment regimens for patients with multiple myeloma are those that include Bortezomib, Dexamethasone with Thalidomide or Cyclophosphamide, with no difference in response rate and response type, overall survival, progression-free survival and with Similar Toxicity Rates. The regimen that includes Doxorubicin is the regimen with the worst results for this item, so we do not suggest it as a first-line treatment regimen. On the other hand, we suggest the regimens that include Thalidomide as a first-line treatment due to the improved rates of progression-free survival despite there are no greater differences in response rates compared with the cyclophosphamide-based regimens.
